0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Enzyme-Responsive Double-Locked Photodynamic Molecular Beacon for Targeted Photodynamic Anticancer Therapy

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          An advanced photodynamic molecular beacon (PMB) was designed and synthesized, in which a distyryl boron dipyrromethene (DSBDP)-based photosensitizer and a Black Hole Quencher 3 moiety were connected via two peptide segments containing the sequences PLGVR and GFLG, respectively, of a cyclic peptide. These two short peptide sequences are well-known substrates of matrix metalloproteinase-2 (MMP-2) and cathepsin B, respectively, both of which are overexpressed in a wide range of cancer cells either extracellularly (for MMP-2) or intracellularly (for cathepsin B). Owing to the efficient Förster resonance energy transfer between the two components, this PMB was fully quenched in the native form. Only upon interaction with both MMP-2 and cathepsin B, either in a buffer solution or in cancer cells, both of the segments were cleaved specifically, and the two components could be completely separated, thereby restoring the photodynamic activities of the DSBDP moiety. This PMB could also be activated in tumors, and it effectively suppressed the tumor growth in A549 tumor-bearing nude mice upon laser irradiation without causing notable side effects. In particular, it did not cause skin photosensitivity, which is a very common side effect of photodynamic therapy (PDT) using conventional “always-on” photosensitizers. The overall results showed that this “double-locked” PMB functioned as a biological AND logic gate that could only be unlocked by the coexistence of two tumor-associated enzymes, which could greatly enhance the tumor specificity in PDT.

          Related collections

          Most cited references78

          • Record: found
          • Abstract: found
          • Article: not found

          Photodynamic therapy and anti-tumour immunity.

          Photodynamic therapy (PDT) uses non-toxic photosensitizers and harmless visible light in combination with oxygen to produce cytotoxic reactive oxygen species that kill malignant cells by apoptosis and/or necrosis, shut down the tumour microvasculature and stimulate the host immune system. In contrast to surgery, radiotherapy and chemotherapy that are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, invasion and infiltration of the tumour by leukocytes, and might increase the presentation of tumour-derived antigens to T cells.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Nanoparticles in photodynamic therapy.

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The present and future role of photodynamic therapy in cancer treatment.

              It is more than 25 years since photodynamic therapy (PDT) was proposed as a useful tool in oncology, but the approach is only now being used more widely in the clinic. The understanding of the biology of PDT has advanced, and efficient, convenient, and inexpensive systems of light delivery are now available. Results from well-controlled, randomised phase III trials are also becoming available, especially for treatment of non-melanoma skin cancer and Barrett's oesophagus, and improved photosensitising drugs are in development. PDT has several potential advantages over surgery and radiotherapy: it is comparatively non-invasive, it can be targeted accurately, repeated doses can be given without the total-dose limitations associated with radiotherapy, and the healing process results in little or no scarring. PDT can usually be done in an outpatient or day-case setting, is convenient for the patient, and has no side-effects. Two photosensitising drugs, porfirmer sodium and temoporfin, have now been approved for systemic administration, and aminolevulinic acid and methyl aminolevulinate have been approved for topical use. Here, we review current use of PDT in oncology and look at its future potential as more selective photosensitising drugs become available.
                Bookmark

                Author and article information

                Journal
                J Am Chem Soc
                J Am Chem Soc
                ja
                jacsat
                Journal of the American Chemical Society
                American Chemical Society
                0002-7863
                1520-5126
                24 March 2023
                05 April 2023
                : 145
                : 13
                : 7361-7375
                Affiliations
                []Department of Chemistry, The Chinese University of Hong Kong , Shatin, N.T., Hong Kong, China
                []Department of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong , Tat Chee Avenue, Kowloon, Hong Kong, China
                [§ ]Department of Clinical Pathology, Pamela Youde Nethersole Eastern Hospital , Chai Wan, Hong Kong, China
                []School of Life Sciences, The Chinese University of Hong Kong , Shatin, N.T., Hong Kong, China
                Author notes
                Author information
                https://orcid.org/0000-0003-3858-3312
                https://orcid.org/0000-0001-5155-7173
                https://orcid.org/0000-0001-9087-960X
                https://orcid.org/0000-0002-0315-8538
                Article
                10.1021/jacs.2c13732
                10080691
                36961946
                93a298ba-529c-4658-bc58-2acd88c1735c
                © 2023 The Authors. Published by American Chemical Society

                Permits the broadest form of re-use including for commercial purposes, provided that author attribution and integrity are maintained ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 24 December 2022
                Funding
                Funded by: Research Grants Council, University Grants Committee, doi 10.13039/501100002920;
                Award ID: 11303517
                Categories
                Article
                Custom metadata
                ja2c13732
                ja2c13732

                Chemistry
                Chemistry

                Comments

                Comment on this article